Hutchmed (China) Newsroom

Hehuang Pharmaceutical (00013.HK): Syvortinib successfully renewed health insurance negotiations, US production is about to be reported

soochowDec 1 07:12

CICC: Maintains hutchmed (china) 'outperform' rating with a target price of HK$38.25.

Zhitong FinanceNov 8 09:33

Hehuang Pharmaceutical (00013.HK): FRUZAQLA met expectations for the third quarter ESLIM-01 data update

china international capital corporationNov 8 07:47

Brokerage Focus: Northeast Securities maintains a "buy" rating on Hutchmed (China) (00013), pointing out its wide product market space and the potential for continuous overseas expansion.

King Gold Financial NewsOct 17 15:20

Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.

Zhitong FinanceOct 17 09:53

Hehuang Pharmaceutical (00013) Company News Review: Phase II clinical trials of sevotinib combination therapy showed improvement in ORR

Northeast SecuritiesOct 16 18:41

swhy: First initiated a "buy" rating on hutchmed (china) (00013) with a target price of 35.4 Hong Kong dollars

Zhitong FinanceSep 25 17:26

Hehuang Pharmaceutical (00013.HK): Focus on the small molecule field of fruquintinib to achieve overseas commercialization

swhy researchSep 25 12:16

Citi: Maintains 'buy' rating on hutchmed (china) (00013), target price reduced to 38.9 Hong Kong dollars

Zhitong FinanceSep 2 13:30

Huhuang Pharmaceutical (0013.HK): Overseas sales of furoquintinib exceeded expectations, and the innovation pipeline accelerated

Aug 9 18:36

Hutchison Whampoa (00013.HK): Continued progress in overseas sales

Aug 7 07:21

US stocks change: Hutchmed (China) rose more than 7% in pre-market trading. CMB International raised its target price for H shares and maintained a 'buy' rating.

Gelonghui FinanceAug 6 16:16

Robust Sales and Expansion Potential Underpin Buy Rating for HUTCHMED

TipRanksAug 5 18:27

CMB International: Maintains a 'buy' rating for Hutchmed (China) (00013) with a target price increase to HKD35.61.

Zhitong FinanceAug 5 11:34

Hutchison Pharmaceutical (00013.HK): Hutchison Pharmaceutical's performance is in line with expectations, and overseas logic is gradually being implemented

Aug 4 14:06

Huhuang Pharmaceutical (0013.HK): Overall performance in the interim report was in line with expectations, overseas sales of furoquintinib exceeded expectations

Aug 4 07:41

Huhuang Pharmaceutical (00013.HK): Fruquintinib sales in the US exceed expectations, are catalytically intensive

Aug 4 00:00

Hehuang Pharmaceutical (0013.HK): Overseas commercialization of fruquintinib accelerates global innovation pipeline and continues to catalyze

Aug 2 14:26

HUTCHMED(13.HK):FRUQUINTINIB'S OVERSEAS SALES BEAT

招银国际Aug 2 14:06

Bocom intl: maintains a buy rating on hutchmed (china) (00013) with a target price of HKD 40.40.

Zhitong FinanceAug 2 10:04